Loading…

Harrow, Inc.HROWCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Ophthalmic pharma selling branded eye-care drugs (Vevye, Iheezo) and compounded medications through its ImprimisRx pharmacy.

Momentum neutral 49
Mkt cap
$1.21B
US dollars, full cap
Free float
85%
of shares outstanding
$/day
$20.7M
20-day average traded
Fwd P/E
26.8×
forward earnings
ROIC−WACC
-5.6 pp
WACC 6.4%
Hurdle
n/a
no reverse DCF
Official | Implied
B3 / B-
agencies · bond market
Next earnings
110 days
8 Mar 2027
Close · USD$32.16
1D+8.9%
1W+9.5%
1M+14.6%
3M-23.5%
6M+4.2%
YTD-34.4%
1Y-20.2%
ATR %5.8%
Beta1.40
52w lowhigh41.4% off high

What Harrow does

Ophthalmic pharma selling branded eye-care drugs (Vevye, Iheezo) and compounded medications through its ImprimisRx pharmacy.

Started as a compounding pharmacy supplying eye doctors with custom-made formulations, which still brings steady sales, and is now building a branded-drug business through its own sales force, so approved products compete for the same prescribers. It also holds minority stakes in other eye-drug companies it helped create.

Products and services

  • Vevye (dry eye)
  • Iheezo (ocular anesthetic)
  • ImprimisRx compounded formulations

Customers

  • Ophthalmologists
  • Optometrists

Where it sits in the supply chain

  • Ophthalmology pharmaceuticals
  • Compounding pharmacy + branded drug…
  • Eye-care specialty sales

What could go right

  • Vevye/Iheezo prescription ramp
  • Bolt-on eye-care drug acquisitions

What could go wrong

  • Regulatory scrutiny of compounding pharmacies
  • Reimbursement/payer coverage friction

Moat: narrow (IP / patents, distribution). Combines branded FDA-approved drugs with a compounding pharmacy niche competitors don't easily replicate.

Headquarters: Nashville, Tennessee, US · Employees: 373

Named competitors

Harrow at a glance

Size Harrow (HROW) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.21B, the 2118th largest of 3,085 United States companies the cockpit tracks. Shares closed at $32.16 on 18 Nov 2026.

Performance Over six months the shares gained 4.2%, against -20.6% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue grew 21.3% over the last twelve months (peer median +5.9%); the operating margin is 0.8% (peer median -18.6%).

Valuation It trades at 26.8× forward earnings against a peer median of 18.6× (3rd most expensive of 10).

Capital Return on invested capital runs 5.6 points below its cost of capital (6.4% WACC).

Credit Harrow has 1 bond outstanding ($300M), rated B3 by the agencies and trading like B- at a weighted spread of 483 bp.

Short interest Short interest is 18.9% of the free float (30 Oct 2026).

Next results Next results expected around 8 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026HROW 98Peer median 81
Six months, rebased to 100: Harrow against the median of its 20 peers (local-currency closes).

Harrow financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$303M$272M$200M$130M$88.6M
Revenue growth—+36%+53%+47%—
Gross profit$223M$204M$150M$90.6M$63.2M
EBITDA$24.8M$57.5M$22.9M$12.9M$5.48M
Net income-$28.5M-$5.14M-$17.5M-$24.4M-$14.1M
Free cash flow-$20.4M$43.0M-$23.8M$2.38M-$892,000
Capital expenditure$19.5M$1.10M$38.7M$153M$7.77M
Total debt$301M$252M$229M$191M$112M

Quarterly statements and history in the cockpit →

Harrow competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%26163000062493347850IDIA300026688321AVLN688443NKTRGPCR6855000950000989GHRSAMPH0023324547HROW6-month return →1-month return →
Up and to the right = strong over both horizons. Harrow is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%0×200×400×300026688321000950688076000989300204AMPH4547HROWRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Harrow is the large dot.

Harrow competitors and peer comparison

Head to head with its named competitors (HROW vs TARS vs BLCO.TO)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Harrow HROW$1.21B+4%+21%1%26.8×n/a
Tarsus Pharmaceuticals TARS$3.74B+17%+86%-10%n/a34.7%
Bausch + Lomb BLCO.TO$7.41B+35%+11%9%18.3×12.0%

How Harrow compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Harrow against its 20 peers (data as of 18 Nov 2026)
MeasureHROWPeer medianRank in peer set
1-month return+14.6%-5.4%3rd highest of 21
6-month return+4.2%-20.6%3rd highest of 21
Distance from 52-week high-41.4%-39.5%11th highest of 21
Revenue growth (TTM)+21.3%+5.9%6th highest of 18
Operating margin0.8%-18.6%9th highest of 18
Forward P/E26.8×18.6×3rd most expensive of 10
ROIC minus cost of capital-5.6 pp-8.4 pp9th highest of 17
EV / EBITDA57.8×n/a—
Net debt / EBITDA9.1×n/a—
Bond spread483 bpn/a—

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Harrow HROWUnited States$1.21B+4%+21%1%26.8×n/an/a
CStone Pharmaceuticals 2616.HKHong Kong$1.21B-22%+117%-89%n/an/an/a
Chongqing Lummy Pharmaceutical 300006.SZChina$1.21B+26%-6%-19%n/a44.1%-13.2%
Mabwell (Shanghai) Bioscience 2493.HKHong Kong$1.20B-29%+21%-127%n/an/an/a
D&D Pharmatech 347850.KSSouth Korea$1.22B-49%-77%-2,324%n/an/an/a
Idorsia IDIA.SWSwitzerland$1.22B-9%-5%-70%n/an/an/a
Tianjin Chase Sun Pharmaceutical 300026.SZChina$1.23B-10%-29%3%21.3×7.0%-5.3%
Shenzhen Chipscreen Biosciences 688321.SSChina$1.18B-38%+27%12%60.4×n/an/a
Avalyn Pharma AVLNUnited States$1.23B-1%n/an/an/an/an/a
Chongqing Genrix Biopharmaceutical 688443.SSChina$1.18B-22%+256%-27%n/an/an/a
Nektar Therapeutics NKTRUnited States$1.18B-50%-17%-304%n/an/an/a
Structure Therapeutics, Inc. Sponsored ADR GPCRUnited States$1.24B-53%n/an/an/an/an/a
Ascentage Pharma Group International 6855.HKHong Kong$1.18B-34%+70%-220%n/an/an/a
C.Q. Pharmaceutical 000950.SZChina$1.24B-27%-3%1%18.6×n/an/a
Sinopep-Allsino Bio Pharmaceutical 688076.SSChina$1.25B-16%+14%19%11.9×3.4%+27.9%
Jiuzhitang 000989.SZChina$1.16B-7%+46%19%22.1×-4.0%-9.0%
GH Research GHRSUnited States$1.25B-19%n/an/an/an/an/a
Staidson (Beijing) Biopharmaceuticals 300204.SZChina$1.26B-41%-24%-51%522.3×n/an/a
Amphastar Pharmaceuticals AMPHUnited States$1.27B+64%+3%19%9.1×2.5%+15.5%
Zhejiang Xianju Pharmaceutical 002332.SZChina$1.28B-1%+8%11%17.7×-0.4%-1.3%
Kissei Pharmaceutical 4547.TJapan$1.14B+3%+6%6%14.5×n/an/a

Harrow bonds and credit

Harrow has 1 bond outstanding with $300M face value. The agencies rate it B3; its bonds trade like B-. Weighted yield 9.44%, a spread of 483 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Harrow's main competitors?
Named competitors: Tarsus Pharmaceuticals (TARS), Bausch + Lomb (BLCO.TO). The cockpit's measured peer set (industry) also includes CStone Pharmaceuticals (2616.HK), Chongqing Lummy Pharmaceutical (300006.SZ), Mabwell (Shanghai) Bioscience (2493.HK), D&D Pharmatech (347850.KS), Idorsia (IDIA.SW), Tianjin Chase Sun Pharmaceutical (300026.SZ).
Is Harrow expensive compared with its peers?
On forward p/e it trades at 26.8× against a peer median of 18.6×, 3rd most expensive of 10 in its peer set.
How has Harrow stock performed?
Over six months to 18 Nov 2026 the shares returned +4.2% against -20.6% for the median peer; over one year -20.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.